Case Study
CASE STUDY TOP 20 GLOBAL DRUG DEVELOPER
dette Software CORPORATION Top-20 Global Drug Developer Automates Forecasting, Optimizes R&D Pipeline Web-based collaboration and advanced-analytic simulation improve R&D portfolio management, optimize strategic and long-range planning,
Full Text
dette Software
CORPORATION
Top-20 Global Drug Developer Automates
Forecasting, Optimizes R&D Pipeline
Web-based collaboration and advanced-analytic simulation improve R&D portfolio management, optimize
strategic and long-range planning, set stage for ???evergreen??? portfolio management.
Facing the odds
Pharmaceutical R&D decision making is
perhaps the most perplexing and high-stakes
responsibility in the modern enterprise. The
reasons are no secret:
* Drug developers make huge investments,
some with 10-year development
timelines, or more.
* They face extreme technical and
regulatory uncertainty about these
investments.
* Meanwhile, they must cross-manage a
vast portfolio of potential products at
varying stages of development.
Drug development pipelines are massive risk
portfolios dotted with a few hard-to-see, and
harder-to-realize, opportunities for reward.
This can frustrate even advanced portfolio
management processes.
It is impossible to know, for example, which
projects will:
* Make it to market
* Fail to gain regulatory approval after
years of investment
* Never make it out of the discovery phase
Yet the pressure to replenish pipelines with
high-potential future revenues is relentless.
Facing these odds, one top-20 global drug
developer approached Vanguard Software
about the possibility of a system that could
help do just that.
Along with many other attributes, the
company wanted a system that could apply
advanced modeling and simulation to
complex drug-development data. The end
goal was to better inform management
decision making. The company was at the
time targeting several challenges.
???Our existing system was time-consuming. It
was difficult to update and maintain the
data, and it offered little flexibility as far as
managing what-if scenarios. It was not able
to provide some of the more advanced
analysis that we wanted. We had to do that
in Excel.??? This is according to an associate
portfolio management director with the
company who spoke recently with Vanguard
Software.
Finding the solution
Initially, the company wanted the ability to
analyze a range of potential outcomes in two
separate areas:
* Line items on the Profit and Loss (P&L)
statement
* Expected R&D spending (taking timeline
uncertainty into account)
In both cases, they wanted to understand
the probability of each possible outcome,
and be able to model individual and
aggregate outcomes under multiple
scenarios, so-called what-if testing.
W: vangua com
1255 Crescent Green #480 Cary, NC 27518 E: info@vanguardsw.com /
CORPORATION
Top-20 Global Drug Developer Automates
Forecasting, Optimizes R&D Pipeline
Web-based collaboration and advanced-analytic simulation improve R&D portfolio management, optimize
strategic and long-range planning, set stage for ???evergreen??? portfolio management.
Facing the odds
Pharmaceutical R&D decision making is
perhaps the most perplexing and high-stakes
responsibility in the modern enterprise. The
reasons are no secret:
* Drug developers make huge investments,
some with 10-year development
timelines, or more.
* They face extreme technical and
regulatory uncertainty about these
investments.
* Meanwhile, they must cross-manage a
vast portfolio of potential products at
varying stages of development.
Drug development pipelines are massive risk
portfolios dotted with a few hard-to-see, and
harder-to-realize, opportunities for reward.
This can frustrate even advanced portfolio
management processes.
It is impossible to know, for example, which
projects will:
* Make it to market
* Fail to gain regulatory approval after
years of investment
* Never make it out of the discovery phase
Yet the pressure to replenish pipelines with
high-potential future revenues is relentless.
Facing these odds, one top-20 global drug
developer approached Vanguard Software
about the possibility of a system that could
help do just that.
Along with many other attributes, the
company wanted a system that could apply
advanced modeling and simulation to
complex drug-development data. The end
goal was to better inform management
decision making. The company was at the
time targeting several challenges.
???Our existing system was time-consuming. It
was difficult to update and maintain the
data, and it offered little flexibility as far as
managing what-if scenarios. It was not able
to provide some of the more advanced
analysis that we wanted. We had to do that
in Excel.??? This is according to an associate
portfolio management director with the
company who spoke recently with Vanguard
Software.
Finding the solution
Initially, the company wanted the ability to
analyze a range of potential outcomes in two
separate areas:
* Line items on the Profit and Loss (P&L)
statement
* Expected R&D spending (taking timeline
uncertainty into account)
In both cases, they wanted to understand
the probability of each possible outcome,
and be able to model individual and
aggregate outcomes under multiple
scenarios, so-called what-if testing.
W: vangua com
1255 Crescent Green #480 Cary, NC 27518 E: info@vanguardsw.com /